Telix Radiopharmaceutical Production Facility Buildout Commences MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE...
EAU Updates Guidance for PSMA-PET Imaging MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus MELBOURNE, Australia and ATHENS, Greece...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix...
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA MELBOURNE, Australia and LIÈGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer MELBOURNE, Australia and NANTES, France, Dec. 20, 2021...
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix® MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE...
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021...
Australian TGA Approves Illuccix® for Prostate Cancer Imaging MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals...
First Cyclotron Removed from Seneffe Production Facility by SCK CEN Decommissioning the first step in Telix Pharmaceuticals’ plan to commence...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer Potential Indication Expansion for Telix’s Core Kidney...
Telix Establishes Commercial Hub in Geneva, Switzerland MELBOURNE, Australia and GENEVA, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE...
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021...
Telix In-Licences Novel Tumour Microenvironment PET Tracer MELBOURNE, Australia and LIÈGE, Belgium, Sept. 09, 2021 (GLOBE NEWSWIRE...
Support
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads